Patent Application
20050277627
The present invention relates to vascular damaging agents, to the use of compounds of the invention in the manufacture of medicaments for use in the production of antiangiogenic effects in warm-blooded animals such as humans, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds as active ingredient, to methods for the treatment of disease states associated with angiogenesis and to the use of such compounds as medicaments.
Normal angiogenesis plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function. Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature Medicine 1: 27-31). Formation of new vasculature by angiogenesis is a key pathological feature of several diseases (J. Folkman, New England Journal of Medicine 333, 1757-1763 (1995)). For example, for a solid tumour to grow it must develop its own blood supply upon which it depends critically for the provision of oxygen and nutrients; if this blood supply is mechanically shut off the tumour undergoes necrotic death. Neovascularisation is also a clinical feature of skin lesions in psoriasis, of the invasive pannus in the joints of rheumatoid arthritis patients and of atherosclerotic plaques. Retinal neovascularisation is pathological in macular degeneration and in diabetic retinopathy.
Reversal of neovascularisation by damaging the newly-formed vascular endothelium is expected to have a beneficial therapeutic effect. The present invention is based on the discovery of tricyclic compounds that surprisingly specifically damage newly formed vasculature without affecting the normal, established vascular endothelium of the host species, a property of value in the treatment of disease states associated with angiogenesis such as cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation.
Compounds of the present invention are colchinol derivatives. Colchinol derivatives for example N-acetyl-colchinol are known. Anti-tumour effects have been noted on animal models (see for example—Jnl. Natl. Cancer Inst. 1952, 13, 379-392). However, the effect studied was that of gross damage (haemorrhage, softening and necrosis) and there is no suggestion of treatment of inappropriate angiogenesis by destruction of neovasculature.
It is believed, though this is not limiting on the invention, that the use of compounds of the invention damages newly-formed vasculature, for example the vasculature of tumours, thus effectively reversing the process of angiogenesis as compared to known anti-angiogenic agents which tend to be less effective once the vasculature has formed.
According to one aspect of the present invention there is provided a compound of the formula I:
wherein:
R1, R2 and R3 are each independently hydroxy, phosphoryloxy (—OPO3H2), C1-4alkoxy or an in vivo hydrolysable ester of hydroxy; with the proviso that at least two of R1, R2 and R3 are C1-4alkoxy;
R4 and R6 are each independently selected from:
hydrogen, nitro, amino, N—C1-4alkylamino, N,N-di(C1-4alkyl)amino, hydroxy, fluoro, C1-4alkoxy and C1-4alkyl;
R5 is selected from one of the following groups:
1) of the formula -A-X1—Y1—B, wherein:
A is C1-4alkylene or —(CH2)p-Q- (wherein p is 0, 1 or 2 and Q is phenylene or thienylene);
X1 is —O—, —CO—, —C(O)O—, —CON(R10)—, —N(R10)—, —N(R10)CO—, N(R10)C(O)O—, —N(R10O)CON(R11)—, —N(R10)SO2—, —SO2N(R10)— or OC(O)N(R10)—
(wherein R10 is hydrogen, C1-3alkyl, hydroxyC2-3alkyl, aminoC2-3alkyl or C1-3alkoxyC2-3alkyl);
Y1 is C1-3alkylene;
B is carboxy, sulpho, phosphoryloxy, hydroxy, amino, N—(C1-4alkyl)amino, N,N-di(C1-3alkyl)amino (wherein the C1-alkyl group in the alkylated amino groups is optionally substituted by hydroxy or amino), —R12 or —NHC(R13)COOH;
(wherein R12 is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O, S and N, which heterocyclic group is optionally substituted by 1 or 2 substituents selected from:
R13 is an amino acid side chain;
2) of the formula:
wherein: the phenyl ring is substituted by —X2—R15 in the 3- or 4-position;
X2 is —CO— or of the formula —(CH2)r— (wherein r is 0, 1, 2 or 3) and R15 is a 5-6 membered saturated heterocyclic group (linked via a ring carbon or nitrogen atom) containing 1 or 2 ring heteroatoms selected from O, S and N, which heterocyclic group is optionally substituted by 1 or 2 substituents selected from
provided that the heterocyclic group (R15) is substituted by at least one substituent selected from C2-4alkanoyl, carbamoyl, N—C1-4alkylcarbamoyl and N,N-di(C1-4alkyl)carbamoyl;
3) —(CH2)a—Y2—(CH2)b—R15 (wherein a is 0, 1, 2, 3 or 4; b is 0, 1, 2, 3 or 4; Y2 is a direct bond, —O—, —C(O)—, —N(R16)—, —N(R16)C(O)— or —C(O)N(R16)— (wherein R16 is hydrogen, C1-3alkyl, hydroxyC2-3alkyl, aminoC2-3alkyl or C1-3alkoxyC2-3alkyl) and wherein 1 or 2 of the (CH2)a or (CH2)b groups are optionally substituted by 1 or 2 substituents selected from hydroxy and amino and R15 is as hereinabove defined; provided that when a is 0, then y2 is a single direct bond;
4) N,N-di(C1-4alkyl)carbamoylC1-4alkyl- (wherein the alkyl groups are independently optionally substituted by 1 or 2 substituents selected from:
provided that:
a) when A is C1-4alkylene and X1 is of the formula —CO—, —N(R10)—, —N(R10)CO— or —CON(R10)— then when B is R12, R12 is as defined hereinabove for R15;
b) when A is C1-4alkylene and X1 is of the formula —N(R10)CO—, —CON(R10)—, or —C(O)O—, then B is not carboxy;
c) when A is C1-4alkylene and X1 is —CONH— or —NHCO—, then B is not carboxy, hydroxy, phosphoryloxy, amino, N—C1-4alkylamino or N,N-di-C1-4alkylamino;
RS is a group —Y3R17 (wherein Y3 is a direct bond, —C(O)—, —C(O)O—, —N(R18)—, —C(O)N(R18)—, —SO2— or —SO2NR18— wherein R18 is hydrogen, C1-3alkyl, hydroxyC2-3alkyl, aminoC2-3alkyl or C1-3alkoxyC2-3alkyl) and R17 is selected from one of the following 4 groups:
1) hydrogen, C1-4alkyl, phenyl, C1-4alkylY4C1-4alkyl (wherein Y4 is —C(O)—, —NR19C(O)— or —C(O)NR19— (wherein R19 is hydrogen, C1-3alkyl, hydroxyC2-3alkyl, aminoC2-3alkyl or C1-3alkoxyC2-3alkyl));
[which alkyl, alkylY4alkyl or phenyl group is optionally substituted by 1 or 2 substituents selected from:
halogeno, amino, N—C1-4alkylamino, N,N-di(C1-4alkyl)amino, hydroxy, carboxy, —CON(R23)R24 (wherein R23 and R24 are independently selected from hydrogen, C1-3alkyl, hydroxyC2-3alkyl, aminoC2-3alkyl and C1-3alkoxyC2-3alkyl), C1-4alkoxy, C1-4alkoxycarbonylamino, C1-4alkanoyl, sulpho, phosphoryloxy, R12 (wherein R12 is as hereinabove defined), and a group —Y5R20 [wherein Y5 is —NR21C(O)— or —OC(O)— (wherein R21 represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R20 is C1-4alkyl or a group R22 (wherein R22 is a 5 or 6 membered aromatic heterocyclic group containing 1 to 4, inclusive, ring heteroatoms selected independently from O, N and S, which aromatic heterocyclic group is optionally substituted by 1 or 2 substituents selected from hydroxy, amino, C1-4alkyl, aminoC1-4alkyl, N—C1-4alkylamino1-4alkyl, N,N-di(C1-4alkyl)aminoC1-4alkyl, carboxy, —CONR25R26 and —NR25COR27 (wherein R25 and R26, which may be the same or different, are hydrogen, C1-3alkyl, hydroxyC2-3alkyl, aminoC2-3alkyl or C1-3alkoxyC2-3alkyl and R27 is C1-3alkyl, hydroxyC2-3alkyl, aminoC2-3alkyl or C1-3alkoxyC2-3alkyl))];
2) R22 (wherein R22 is as hereinabove defined);
3) R22—C1-4alkyl- (wherein R22 is as hereinabove defined); or
4) R12Y7C1-4alkyl- (wherein R12 is as hereinabove defined and Y7 is —C(O)—, —NR23C(O)—, —NR23C(O)C1-4alkyl-, —C(O)NR23— or —C(O)NR23C1-4alkyl- (wherein R23 is as hereinabove defined))];
and R9 is hydrogen or C1-3alkyl;
or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.
In another aspect, the invention relates to a compound of the formula (I) as hereinabove defined or to a pharmaceutically-acceptable salt thereof.
In this specification the generic term “alkyl” includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as “propyl” are specific for the straight-chain version only and references to individual branched-chain alkyl groups such as “isopropyl” are specific for the branched-chain version only. An analogous convention applies to other generic terms.
R13 is an amino acid side chain. This includes amino acid side chains from natural and non-natural amino acids and includes the possibility of R13 joining to the NH group so as to form a ring as in the amino acid proline. It includes α-amino acids β-amino acids and γ-amino acids. In addition, the amino acids may be L-isomers or D-isomers, but preferably L-isomers. Preferred amino acids include glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, cysteine, tyrosine, asparaginine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, β-alanine and ornithine. More preferred amino acids include glutamic acid, serine, threonine, arginine, glycine, alanine, β-alanine and lysine. Especially preferred amino acids include glutamic acid, serine, threonine, arginine, alanine and β-alanine. Specific values for R12 include hydrogen, C1-4alkyl, C1-4alkylthioC1-4alkyl, hydroxyC1-4alkyl, thioC1-4alkyl, phenylC1-4alkyl (optionally substituted by hydroxy), guanidinoC1-4alkyl, carboxyC1-4alkyl, carbamoylC1-4alkyl, aminoC1-4alkyl and imidazolyl C1-4alkyl and R12 forming a pyrrolidinyl ring with the NH group. Preferred values for R13 include hydrogen, C1-4alkyl, C1-4alkylthioC1-4alkyl, hydroxyC1-4alkyl, thioC1-4alkyl, guanidinoC1-4alkyl, carboxyC1-4alkyl, carbamoylC1-4alkyl and aminoC1-4alkyl.
In this specification, the term heteroaryl is used to describe fully saturated heterocyclic rings. Examples of 5- or 6-membered heteroaryl rings include pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, thienyl, furyl and oxazolyl.
It is to be understood that, insofar as certain of the compounds of Formula I defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses vascular damaging activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.
Suitable values for the generic radicals referred to above include those set out below. Within the present invention it is to be understood that a compound of the formula I or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which has vascular damaging activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.
It is also to be understood that certain compounds of the formula I and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which have vascular damaging activity.
The present invention relates to the compounds of formula I as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula I as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include for example salts with inorganic or organic acids affording pharmaceutically acceptable anions such as with hydrogen halides (especially hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid. Suitable salts include hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates and tartrates. In addition where the compounds of formula I are sufficiently acidic, pharmaceutically acceptable salts may be formed with an inorganic or organic base which affords a pharmaceutically acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
Various forms of prodrugs are known in the art. For examples of such prodrug derivatives, see: a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 “Design and Application of Prodrugs”, by H. Bundgaard p. 113-191 (1991); c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); d) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); and e) N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984).
Examples of such pro-drugs may be used to form in-vivo-cleavable esters of a compound of the Formula I. An in-vivo-cleavable ester of a compound of the Formula I containing a carboxy group is, for example, a pharmaceutically-acceptable ester which is cleaved in the human or animal body to produce the parent acid. Suitable pharmaceutically-acceptable esters for carboxy include C1-6alkoxymethyl esters, for example methoxymethyl; C1-6alkanoyloxymethyl esters, for example pivaloyloxymethyl; phthalidyl esters; C3-8cycloalkoxycarbonyloxy C1-6alkyl esters, for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolan-2-ylmethyl esters, for example 5-methyl-1,3-dioxolan-2-ylmethyl; and C1-6alkoxycarbonyloxyethyl esters, for example 1-methoxycarbonyloxyethyl; and may be formed at any carboxy group in the compounds of this invention.
Suitable values for R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 or R16 or for various substituents on D, R12, R14 or R15 include:
Examples of 5- or 6-membered saturated heterocyclic ring ring systems include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl and morpholinyl. Preferably at least 2 of R1, R2, and R3 are methoxy.
Preferably R1, R2, and R3 are all C1-4alkoxy.
Most preferably R1, R2, and R3 are all methoxy.
Preferably A is ethylene, propylene, benzylene or phenylene. More preferably A is ethylene or phenylene.
More preferably A is phenylene.
Most preferably A is 1,4-phenylene.
Preferably X1 is —CO—, —CON(R10)—, —N(R10)—, —N(R10)CO— or —OC(O)N(R10)—.
Most preferably X1 is —CO— or —N(R10)CO—.
Preferably R10 is hydrogen or methyl. Most preferably R10 is hydrogen.
Preferably Y1 is propylene or ethylene.
More preferably Y1 is ethylene.
Preferably B is carboxy sulpho, phosphoryloxy or of the formula —R12 wherein R12 is as hereinabove defined.
Yet more preferably B is phosphoryloxy or —R12. Most preferably, B is —R12.
Preferably R12 is a 5 or 6 membered saturated heterocyclic ring containing 1 or 2 ring heteratoms selected from N and O.
Preferably R12 is a 6 membered saturated heterocyclic ring containing 1 or 2 ring heteratoms selected from N and O.
Preferably —R12 contains at least 1 ring nitrogen atom.
Preferably —R12 is piperazinyl, morpholinyl, pyrrolidiyl or piperidinyl, each of which is linked via a ring carbon or nitrogen ring atom and each ring is optionally substituted by 1 or 2 of the substituents mentioned above for —R12.
Preferably —R12 is linked via a ring nitrogen atom.
More preferably —R12 is piperazino or morpholino, each ring being optionally substituted by 1 or 2 of the substituents mentioned hereinabove for —R12.
The saturated heterocyclic ring may be substituted on ring carbon or ring nitrogen atoms, providing this does not result in quaternisation.
When the saturated heterocyclic ring contains a ring nitrogen atom which is not linked to Y1, preferably this ring nitrogen atom is substituted.
Preferred substituents for the saturated heterocyclic ring in R12 include C1-4 alkyl, C2-4alkanoyl, carbamoyl, cyanoC1-3alkyl, hydroxyC1-3alkyl, carboxyC1-3alkyl and aminoC1-3alkyl.
More preferred substituents for the saturated heterocyclic ring in —R12 include C1-3alkyl, C2-3alkanoyl, carbamoyl and hydroxyC2-3alkyl.
Yet more preferred substituents for the saturated heterocyclic ring in —R12 include methyl, ethyl, acetyl, propionyl, carbamoyl and 2-hydroxyethyl.
The most preferred substituents for the saturated heterocyclic ring include methyl, acetyl and carbamoyl.
Preferably the saturated heterocyclic ring in —R12 is unsubstituted or substituted by 1 substituent.
When the saturated heterocyclic ring in —R12 is morpholino, preferably it is unsubstituted. When the saturated heterocyclic ring in —R12 is piperazino, preferably it is unsubstituted or substituted by 1 substituent on a ring nitrogen atom.
Most preferably R12 is morpholino, 4-methylpiperazin-1-yl or 4-acetylpiperazin-1-yl.
Preferably X2 is —(CH2)r—.
Preferably r is 0, 1 and 2.
Most preferably r is 1.
In another aspect r is 0.
In one aspect the —X2—R15 substituent is in the 3-position of the phenyl ring in R5.
In another aspect the —X2—R15 substituent is in the 4-position of the phenyl ring in R5.
Preferably R15 is morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl optionally substituted as hereinabove defined for R12, and substituted by at least 1 substituent selected from C2-4alkanoyl, carbamoyl, N—C1-4-alkylcarbamoyl and N,N-di(C1-4alkyl)carbamoyl.
More preferably R15 is morpholinyl, piperazinyl or piperidinyl linked by either a ring carbon or nitrogen atom, optionally substituted as hereinabove defined for R12 and substituted by at least 1 substituent selected from C2-4alkanoyl, carbamoyl, N—C1-4alkylcarbamoyl and N,N-di(C1-4alkyl)carbamoyl.
More preferably, R15 is morpholino or piperazino, each ring being substituted by 1 substituent selected from C2-3alkanoyl, carbamoyl, N—C1-3alkylcarbamoyl and N,N-di(C1-3alkyl)carbamoyl.
Yet more preferably R15 is piperazin-1-yl which is substituted in the 4-position by 1 substituent selected from acetyl, carbamoyl, N-methylcarbamoyl and N,N-dimethylcarbamoyl.
Preferably —X2—R15 is 4-carbamoylpiperazin-1-ylmethyl or 4-acetylpiperazin-1-ylmethyl.
Preferably a is 0, 1, 2 or 3.
More preferably a is 2 or 3.
Most preferably a is 2.
Preferably b is 0, 1, or 2.
More preferably b is 0 or 1
Most preferably b is 0.
Preferably Y2 is —C(O)—, —N(R16)C(O)— or —C(O)N(R16)—
More preferably Y2 is —C(O)— or —N(R16)C(O)—.
Most preferably Y2 is —C(O)—.
Preferably R16 is hydrogen.
Preferably the alkyl groups in N,N-di(C1-4 alkyl)carbamoylC1-4alkyl in R5 are optionally substituted by 1 or 2 substituents selected from amino, N-methylamino, N—N-dimethylamino, hydroxy, methoxy, carboxy, sulpho and phosphoryloxy.
More preferably the alkyl groups in N,N-di(C1-4alkyl)carbamoylC1-4alkyl in R5 are optionally substituted by substituents selected from amino, hydroxy and phosphoryloxy.
Yet more preferably the alkyl groups in N,N-di(C1-4alkyl)carbamoylC1-4alkyl are optionally substituted by 1 hydroxy substituent.
In one aspect R5 is selected from group 1).
In another aspect R5 is selected from group 2).
In yet another aspect R5 is selected from group 3).
In yet another aspect R5 is selected from group 4).
When R5 is selected from group 1), it is preferably 4-[2-(4-methylpiperazin-1-yl)ethylcarbonylamino]phenyl, 4-[2-(4-acetylpiperazin-1-yl)ethylcarbonylamino]phenyl, 4-[2-(4-methylpiperazin-1-yl)methylcarbonylamino]phenyl or 4-[2-(4-acetylpiperazin-1-yl)methylcarbonylamino]phenyl.
When R5 is selected from group 2), it is preferably 4-(4-acetylpiperazin-1-ylmethyl)phenyl or 3-(4-acetylpiperazin-1-ylmethyl)phenyl.
When R5 is selected from group 3), it is preferably, 2-(4-acetylpiperazin-1-ylcarbonyl)ethyl or 3-(4-acetylpiperazin-1-ylcarbonyl)propyl.
Preferably when R5 is selected from group 4), it is N—N-di-(2-hydroxyethyl)carbamoylC1-4alkyl.
Most preferably when R5 is selected from group 4), it is 2-[N—N-di-(2-hydroxyethyl)carbamoyl]ethyl or 3-[N,N-di-(2-hydroxyetnyl)carbamoyl]propyl.
Preferably Y3 is —C(O)—, —C(O)O— or —C(O)N(R18)—. More preferably Y3 is —C(O)— or —C(O)O—.
Most preferably Y3 is —C(O)—.
Preferably R18 is hydrogen, methyl, 2-hydroxyethyl or 2-aminoethyl.
Most preferably R18 is hydrogen.
Preferably R19 is hydrogen or methyl. Most preferably R19 is hydrogen.
Preferably Y4 is —NHCO— or —CONH—.
Preferred optional substituents for alkyl, alkylY4 alkyl and phenyl groups in R17 include: halogeno, amino, N—C1-4alkylamino, N,N-di(C1-4alkyl)amino, C1-4alkoxy, C1-4alkoxycarbonylamino, C1-4 alkanoyl, phosphoryloxy, R12 (wherein R12 is as hereinabove defined), —Y5R20 [wherein Y5 is —NHCO—; and R20 is C1-4alkyl or R22 (wherein R22 is as hereinabove defined)].
More preferred optional substituents for alkyl, alkylY4alkyl and phenyl groups include: fluoro, chloro, bromo, amino, methoxy, methoxycarbonylamino, acetyl, phosphoryloxy, R12 (wherein R12 is as hereinabove defined), —Y5R20 [wherein Y5 is —NHCO—; and R20 is methyl, ethyl or R22 (wherein R22 is as hereinabove and hereinbelow defined)].
Yet more preferably, optional substituents for alkyl, alkylY4 alkyl and phenyl groups in R17 include fluoro, chloro and bromo. Most preferably alkyl and alkylY4 alkyl groups in R17 are unsubstituted.
Preferably R21 is hydrogen.
Preferably R22 is optionally substituted: imidazolyl, pyridyl, pyrimidyl, thiazolyl or pyrazinyl.
More preferably R22 is optionally substituted: imidazolyl.
A preferred optional substituent for the aromatic heterocyclic group in R22 is C1-4alkyl.
A more preferred optional substituent for the aromatic heterocyclic group in R22 methyl.
The aromatic heterocyclic group in R22 may be unsubstituted.
Preferably R23 and R24 are independently hydrogen or methyl.
More preferably R23 and R24 are hydrogen.
Preferably R25 and R26 are independently selected from hydrogen and methyl. More
Preferably R25 and R26 are hydrogen.
Preferably R27 is C1-3alkyl.
More preferably R27 is methyl.
Preferably R22—C1-4 alkyl in group 3) of R8 is R22-methylene, R22-propylene.
More preferably R22—C1-4 alkyl is R22-ethylene.
Preferably Y7 is —N(R23)C(O)— or —CON(R23)—.
More preferably Y7 is —N(R23)C(O)— or —CON(R23)—.
More preferably Y7 is —NHC(O)— or —CONH—.
Preferably R17 is methyl, fluoromethyl, difluoromethyl or trifluoromethyl.
More preferably R17 is methyl.
Most preferably R8 is acetyl.
Most preferably R9 is hydrogen.
A preferred class of compound is of the formula (I) wherein:
R1, R2, and R3 are all C1-4alkoxy;
R4 and R6 are independently selected from hydrogen, hydroxy, C1-3 alkoxy, and C1-3alkyl;
R5 is selected from one of the following groups:
1) of the formula -A-X1—Y1—B, wherein:
A is ethylene or phenylene;
Y1 is C1-3alkylene;
X1 is —CO—, —CON(R10)—, —N(R10)—, —N(R10)CO— or —OC(O)N(R10)—;
B is carboxy sulpho, phosphoryloxy or of the formula —R12 (wherein R12 is piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring carbon or nitrogen ring atom and each ring is optionally substituted by 1 or 2 substituents selected from C1-4alkyl, C2-4alkanoyl, carbamoyl, cyanoC1-3alkyl, hydroxyC1-3alkyl, carboxyC1-3alkyl and aminoC1-3alkyl);
2) of the formula
wherein:
the —X2—R15a substituent is in the 3, or 4-position of the phenyl ring;
X2 is —(CH2)r—;
r is 0, 1 and 2; and
R15a is morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl optionally substituted by 1 or 2 substituents selected from C1-4alkyl, C2-4alkanoyl, carbamoyl, cyanoC1-3alkyl, hydroxyC1-3alkyl, carboxyC1-3alkyl and aminoC1-3alkyl; and substituted by at least 1 substituent selected from C2-4alkanoyl, carbamoyl, N—C1-4 alkylcarbamoyl and N,N-di(C1-4alkyl)carbamoyl;
3) of the formula —(CH2)a—Y2—(CH2)b—R15b, wherein:
a is 2 or 3;
b is 0, 1, or 2; and
Y2 is a single direct bond, —C(O)—, —NHC(O)— or —C(O)NH—; and
R15b is morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl optionally substituted by 1 or 2 substituents selected from C1-4alkyl, C2-4alkanoyl, carbamoyl, cyanoC1-3alkyl, hydroxyC1-3alkyl, carboxyC1-3alkyl and aminoC1-3alkyl; and substituted by at least 1 substituent selected from C2-4alkanoyl, carbamoyl, N—C1-4 alkylcarbamoyl and N,N-di(C1-4alkyl)carbamoyl; or
4) N,N-di(C1-4alkyl)carbamoylC1-4alkyl-, wherein the alkyl group is optionally substituted by 1 or 2 substituents selected from amino, N-methylamino, N—N-dimethylamino, hydroxy, methoxy, carboxy, sulpho and phosphoryloxy; and
R8 is a group —Y3R17 (wherein Y3 is —C(O)—, —C(O)O— or —C(O)NH—; and R17 is selected from one of the following 4 groups:
1) hydrogen, C1-4alkyl, phenyl or C1-4alkylY4C1-4alkyl (wherein Y4 is —NHCO— or —CONH—); [which alkyl, alkylY4alkyl or phenyl group is optionally substituted by 1 or 2 substituents selected from:
halogeno, amino, N—C1-4alkylamino, N,N-di(C1-4alkyl)amino, C1-4alkoxy, C1-4alkoxycarbonylamino, C1-4alkanoyl, phosphoryloxy, R12a (wherein R12a is piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring carbon or nitrogen ring atom and each ring is optionally substituted by 1 or 2 of the substituents selected from C1-4alkyl, C2-4alkanoyl, carbamoyl, cyanoC1-3alkyl, hydroxyC1-3alkyl, carboxyC1-3alkyl and aminoC1-3alkyl), —Y5—R20 [wherein Y5 is —NHCO—; and R20 is C1-4alkyl or R22a (wherein R22a is imidazolyl, pyridyl, pyrimidyl, thiazolyl or pyrazinyl, each of which is optionally substituted by C1-4alkyl)];
2) R22a (wherein R22a is as hereinabove defined);
3) R22a—C1-4alkyl- (wherein R22a is as hereinabove defined); or
4) R12aY7C1-4alkyl- (wherein R12a is as hereinabove defined and Y7 is Y7 is —NHC(O)— or —CONH—)];
and R9 is hydrogen;
or a pharmaceutically-aceeptable salt, solvate or pro-drug thereof.
Another preferred class of compound is of the formula (1) wherein:
R1, R2, and R3 are all methoxy;
R4 and R6 are independently selected from hydrogen, hydroxy, methoxy and methyl;
R5 is selected from one of the following groups:
1) of the formula -A-X1—Y1—B, wherein:
A is ethylene or phenylene;
Y1 is C1-3alkylene;
X1 is —CO—, —CON(R10)—, —N(R10)—, —N(R10)CO— or —OC(O)N(R10)—;
B is carboxy sulpho, phosphoryloxy or of the formula —R12 (wherein R12 is
piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring carbon or nitrogen ring atom and each ring is optionally substituted by 1 or 2 substituents selected from C1-4 alkyl, C2-4alkanoyl, carbamoyl, cyanoC1-3alkyl, hydroxyC1-3alkyl, carboxyC1-3alkyl and aminoC1-3alkyl);
2) of the formula
wherein:
the —X2—R15c substituent is in the 3, or 4-position of the phenyl ring;
X2 is —(CH2)r—;
r is 0, 1 and 2; and
R15c is morpholinyl, piperazinyl or piperidinyl optionally substituted by 1 or 2 substituents selected from C1-4 alkyl, C2-4alkanoyl, carbamoyl, cyanoC1-3alkyl, hydroxyC1-3alkyl, carboxyC1-3alkyl and aminoC1-3alkyl; and substituted by at least 1 substituent selected from C2-4alkanoyl, carbamoyl, N—C1-4 alkylcarbamoyl and N,N-di(C1-4alkyl)carbamoyl;
3) of the formula —(CH2)a—Y2—(CH2)b—R15d, wherein:
a is 2 or 3;
b is 0 or 1; and
Y2 is a single direct bond, —C(O)— or —NHC(O)—; and
R15d is morpholinyl, piperazinyl or piperidinyl optionally substituted by 1 or 2 substituents selected from C1-4 alkyl, C2-4alkanoyl, carbamoyl, cyanoC1-3alkyl, hydroxyC1-3alkyl, carboxyC1-3alkyl and aminoC1-3alkyl; and substituted by at least 1 substituent selected from C2-4alkanoyl, carbamoyl, N—C1-4 alkylcarbamoyl and N,N-di(C1-4alkyl)carbamoyl; or
4) N,N-di(C1-4alkyl)carbamoylC1-4alkyl-, wherein the alkyl group is optionally substituted by 1 or 2 substituents selected from amino, N-methylamino, N—N-dimethylamino, hydroxy, methoxy, carboxy, sulpho and phosphoryloxy; and
R8 is a group —Y3R17 (wherein Y3 is —C(O)— or —C(O)O—; and R17 is selected from one of the following 4 groups:
1) C1-4alkyl [which alkyl, group is optionally substituted by 1 or 2 substituents selected from: fluoro, chloro and bromo;
2) R22b (wherein R22b is imidazolyl, pyridyl, pyrimidyl, thiazolyl or pyrazinyl, each of which is optionally substituted by C1-4alkyl);
3) R22b—C1-4alkyl- (wherein R22b is as hereinabove defined); or
4) R12bY7C1-4alkyl- (wherein R12b is morpholinyl, piperidinyl or piperazinyl each of which is optionally substituted by methyl, ethyl, acetyl, propionyl, carbamoyl or 2-hydroxyethyl; and Y7 is —NHC(O)— or —CONH—)];
and R9 is hydrogen;
or a pharmaceutically-aceeptable salt, solvate or pro-drug thereof.
A preferred compound of the present invention is of the formula (II):
wherein R5 and R8 are as hereinabove defined;
or a pharmacetically-acceptable salt, solvate or pro-drug thereof.
Another preferred class of compounds is that of the formula (III) wherein:
R5 is selected from one of the following groups:
1) of the formula -A-X1—Y1—B, wherein:
A is ethylene or phenylene;
Y1 is C1-3alkylene;
X1 is —CO—, —CONH—, —NH—, —NHCO— or —OC(O)NH—;
B is carboxy sulpho, phosphoryloxy or of the formula —R12 (wherein R12 is
piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring carbon or nitrogen ring atom and each ring is optionally substituted by 1 or 2 of the substituents selected from C1-4 alkyl, C2-4alkanoyl, carbamoyl, cyanoC1-3alkyl, hydroxyC1-3alkyl, carboxyC1-3alkyl and aminoC1-3alkyl);
2) of the formula
wherein:
the —X2—R15 substituent is in the 3, or 4-position of the phenyl ring;
X2 is —(CH2)r—;
r is 0, 1 and 2; and
R15 is morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl optionally substituted as immediately hereinabove defined for R12, and substituted by at least 1 substituent selected from C2-4alkanoyl, carbamoyl, N—C1-4 alkylcarbamoyl and N,N-di(C1-4alkyl)carbamoyl;
3) of the formula —(CH2)a—Y2—(CH2)b—R15, wherein:
a is 2 or 3;
b is 0, 1, or 2; and
Y2 is a single direct bond, —C(O)—, —NHC(O)— or —C(O)NH—; or
4) N,N-di(C1-4alkyl)carbamoylC1-4alkyl-, wherein the alkyl group is optionally substituted by 1 or 2 substituents selected from amino, N-methylamino, N—N-dimethylamino, hydroxy, methoxy, carboxy, sulpho and phosphoryloxy;
or a pharmaceutically acceptable salt, solvate or prodrug thereof.
Another preferred class of compounds is that of the formula (III) wherein:
R5 is selected from one of the following groups:
1) of the formula -A-X1—Y1—B, wherein:
A is ethylene or phenylene;
Y1 is C1-3alkylene;
X1 is —CO—, —NHCO—;
B is carboxy sulpho, phosphoryloxy or of the formula —R12 (wherein R12 is
piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring carbon or nitrogen ring atom and each ring is optionally substituted by 1 or 2 of the substituents selected from C1-4 alkyl, C2-4alkanoyl, carbamoyl, cyanoC1-3alkyl, hydroxyC1-3alkyl, carboxyC1-3alkyl and aminoC1-3alkyl);
2) of the formula
wherein:
the —X2—R15a substituent is in the 3, or 4-position of the phenyl ring;
X2 is —(CH2)r—;
r is 1 and 2; and
R15a is as hereinabove defined;
3) of the formula —(CH2)a—Y2—(CH2)b—R15b, wherein:
a is 2 or 3;
b is 0; and
Y2 is a single direct bond, —C(O)—, —NHC(O)— or —C(O)NH—; and
R15b is as hereinabove defined; or
4) N,N-di(C1-4alkyl)carbamoylC1-4alkyl-, wherein the alkyl group is optionally substituted by 1 or 2 substituents selected from amino, hydroxy and phosphoryloxy; or a pharmaceutically acceptable salt, solvate or pro-drug thereof.
Another preferred class of compounds is that of the formula (III) wherein:
R5 is selected from one of the following groups:
1) of the formula -A-X1—Y1—B, wherein:
A is phenylene;
X1 is —CO—, —NHCO—;
Y1 is methylene or ethylene;
B is piperazino or morpholinyl each of which is linked via a ring nitrogen atom and each ring is optionally substituted by 1 methyl or acetyl group;
2) of the formula
wherein:
the —X2—R15e substituent is in the 3, or 4-position of the phenyl ring;
X2 is —(CH2)r—;
r is 1; and
R15e is piperazino or morpholinyl each of which is linked via a ring nitrogen atom and each ring is optionally substituted by 1 methyl or acetyl group;
3) of the formula —(CH2)a—Y2—(CH2)b—R15f, wherein:
a is 2 or 3;
b is 0; and
Y2 is —C(O)—;
R15f is piperazino or morpholinyl each of which is linked via a ring nitrogen atom and each ring is optionally substituted by 1 methyl or acetyl group; or
4) 2-[N,N-di(C1-4alkyl)carbamoyl]ethyl- or 3-[N,N-di(C1-4alkyl)carbamoyl]propyl-, wherein the C1-4alkyl group is optionally substituted by 1 hydroxy group;
or a pharmaceutically acceptable salt, solvate or prodrug thereof.
Yet another preferred class of compounds is that of the formula (III) wherein:
R5 is 2-[N,N-di(C1-4alkyl)carbamoyl]ethyl- or 3-[N,N-di(C1-4alkyl)carbamoyl]propyl-, wherein the C1-4alkyl group is optionally substituted by 1 hydroxy group; or a pharmaceutically acceptable salt, solvate or prodrug thereof. Particular compounds of the present invention include: (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 5-(4-acetylpiperazin-1-yl)-5-oxopentanoate; (5S)-5-acetylamino-9,10,11 -trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 4-(4-acetylpiperazin-1-yl)-4-oxobutanoate; (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3-(4-acetylpiperazin-1-ylmethyl)benzoate; (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 4-[3-(4-methylpiperazin-1-yl)propionylamino]benzoate; (5S)-5-acetylamino-9,10,11 -trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3-(4-carbamoylpiperazin-1-ylmethyl)benzoate; (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl N-acetylpiperidin-1-ylcarboxylate; (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3-[N,N-di-(2-hydroxyethyl)carbamoyl]propanoate; and (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 4-[N,N-di(2-hydroxyethyl)carbamoyl]butanoate; and pharmaceutically-acceptable salts, solvates or pro-drugs thereof.
Synthesis of Compounds of the Formula I
Compounds of Formula I may be prepared by a number of processes as generally described herein below and more specifically in the Examples hereinafter. Processes for the preparation of novel compounds of formula I, are provided as a further feature of the invention and are as described hereinafter. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.
Thus according to another aspect of the invention, a compound of the formula (I) may be formed by deprotecting a compound of the formula (I) wherein at least 1 functional group is protected. For example, amino, hydroxy, carboxy or phosphoryloxy groups may be protected during the reaction sequence used to prepare a compound of the formula (1).
Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods.
Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
A suitable protecting group for a hydroxy group is, for example, an arylmethyl group (especially benzyl), a tri-(1-4C)alkylsilyl group (especially trimethylsilyl or tert-butyldimethylsilyl), an aryldi-(1-4C)alkylsilyl group (especially dimethylphenylsilyl), a diaryl-(1-4C)alkylsilyl group (especially tert-butyldiphenylsilyl), a (1-4C)alkyl group (especially methyl), a (2-4C)alkenyl group (especially allyl), a (1-4C)alkoxymethyl group (especially methoxymethyl) or a tetrahydropyranyl group (especially tetrahydroyran-2-yl). The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal. Alternatively a trialkylsilyl or an aryldialkylsilyl group such as a tert-butyldimethylsilyl or a dimethylphenylsilyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric, phosphoric or trifluoroacetic acid, or with an alkali metal or ammonium fluoride such as sodium fluoride or, preferably, tetrabutylammonium fluoride. Alternatively an alkyl group may be removed, for example, by treatment with an alkali metal (1-4C)alkylsulphide such as sodium thioethoxide or, for example, by treatment with an alkali metal diarylphosphide such as lithium diphenylphosphide or, for example, by treatment with a boron or aluminium trihalide such as boron tribromide. Alternatively a (1-4C)alkoxymethyl group or tetrahydropyranyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric or trifluoroacetic acid.
Alternatively a suitable protecting group for a hydroxy group is, for example, an acyl group, for example a (2-4C)alkanoyl group (especially acetyl) or an aroyl group (especially benzoyl). The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
A suitable protecting group for an amino, imino or alkylamino group is, for example, an acyl group, for example a (2-4C)alkanoyl group (especially acetyl), a (1-4C)alkoxycarbonyl group (especially methoxycarbonyl, ethoxycarbonyl or tert-butoxycarbonyl), an arylmethoxycarbonyl group (especially benzyloxycarbonyl) or an aroyl group (especially benzoyl). The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl, alkoxycarbonyl or aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid, and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a (1-4C)alkyl group (especially methyl or ethyl) which may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide; or, for example, a tert-butyl group which may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid.
In the following process description (the symbols R1—R7, A, B, D, Ra, Rb, a and b are to be understood to represent those groups described above in relation to formulae (I), (II) and (III) unless otherwise stated.
A compound of the formula (I), or a compound of the formula (I) wherein at least 1 functional group is protected, may be prepared using one of the following processes:
(a) reacting a compound of the formula (X):
with a compound of the formula R5—COOH or an activated derivative thereof;
(b) when R5 is of the formula:
reacting a compound of the formula (XI):
with R15 (wherein L1 is a leaving group);
(c) introducing substituents onto a ring nitrogen atom in R12 or R15;
(d) converting one compound of the formula (I) into another compound of the formula (I);
(e) when a phosphoryloxy group is desired, reacting the corresponding hydroxy compound with a phosphoramidite;
wherein any functional groups are optionally protected.
and thereafter if necessary:
i) converting a compound of formula (I) into another compound of formula (I);
ii) removing any protecting groups;
iii) forming a pharmaceutically acceptable salt, solvate or pro-drug thereof.
The reaction between a compound of the formula (X) and a compound of the formula R5—COOH or an activated derivative thereof is performed under standard coupling conditions. For example, in the presence of a coupling agent such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and optionally a base, for example an organic base such as triethylamine or DMAP. The reaction is conveniently carried out in a solvent such as an aprotic solvent, for example dimethylformamide, or in a chlorinated solvent, for example trichloromethane or dichloromethane, and at a temperature in the range of about −30° C. to about 60° C. Conveniently at or near ambient temperature.
When X2 is —(CH2)r, the reaction between a compound of the formula (XI) and R15 is conveniently carried out in an inert organic solvent such as acetonitrile, in a temperature range of 0° C. to 60° C., normally at ambient temperature. Suitable leaving groups (L1) include halogeno, mesyloxy and tosyloxy. Preferably halogeno, and particularly chloro or iodo.
When X2 is —CO—, L1 is usually chloro and the reaction is normally carried out in a chlorinated solvent such as dichloromethane. The reaction is carried out in the presence of a base such as triethylamine and in a temperature range of 0 to 60° C., normally about ambient temperature.
Substituents, such as C1-4alkyl, C2-4alkanoyl, carbamoyl and alkylated carbamoyl groups, can be in introduced onto a ring nitrogen atom in R12 or R15, using standard conditions known in the art for alkylation and acylation of an amino group. Alkylations are normally carried out by reacting a ring-nitrogen containing R12 or R15 with the appropriate alkylating agent, such as an alkyl halide, an alkyl toluenesulphonate, an alkyl methanesulphonate or an alkyl triflate. The alkylation reaction can be carried out in the presence of a base for example an inorganic base such as a carbonate e.g. caesium or potassium carbonate, a hydride such as sodium hydride or an alkoxide such as potassium tert-butoxide in a suitable solvent such as an aprotic solvent e.g. dimethylformamide or an ether solvent such as tetrahydrofuran at a temperature of around −10° C. to 80° C.
Acylation of a ring nitrogen in R12 or R15 is carried out by reacting the saturated heterocyclic ring with an acylating agent, for example, an acyl halide or anhydride in the presence of a base, for example a tertiary amine base such as triethylamine, in for example, a solvent such as a hydrocarbon solvent e.g. dichloromethane, at a temperature in the range for example −30° C. to 120° C., conveniently at or near ambient temperature.
A carbamoyl group can be introduced by reacting the saturated heterocyclic ring with a tri(alkyl)silyl isocyanate in an inert organic solvent such as dichloromethane.
A compound of formula I may also be prepared from another compound of formula I by chemical modification. Examples of such chemical modifications include standard alkylation, arylation, heteroarylation, acylation, sulphonylation, phosphorylation, aromatic halogenation and coupling reactions. These reactions may be used to add new substituents or to modify existing substituents. Alternatively, existing substituents in compounds of formula I may be modified by, for example, oxidation, reduction, elimination, hydrolysis or other cleavage reaction to yield other compounds of formula I. For example a substituent can be introduced onto a ring nitrogen atom in R12 using similar processes to those described above, for the alkylation or acylation of a ring nitrogen.
In another general example an alkoxy group may be cleaved to the corresponding hydroxy group by reaction with boron tribromide, in a solvent such as a chlorinated solvent e.g. dichloromethane, at a low temperature e.g. around −78° C.
A amino group can be alkylated or acylated using similar reaction conditions to those described above for alkylation or acylation of a ring nitrogen atom in R12 or R15.
A compound containing a hydroxy group can be converted into the corresponding phosphoryloxy compound by treatment with for example di-tert-butyl diisopropylphoramidite or di-tert-butyl diethylphosphoramidite, in the presence of a suitable catalyst for example tetrazole. A solvent, such as an ether solvent, for example tetrahydrofuran can be used at a temperature in the range of −40° C. to 40° C., conveniently at or near ambient temperature, followed by treatment with an oxidising agent, such as 3-chloroperoxy benzoic acid. The reaction is carried out at a temperature in the range −78° C. to 40° C., preferably −40° C. to 10° C. The resulting intermediate phosphate triester is treated with an acid for example trifluoroacetic acid in a solvent such as a chlorinated solvent e.g. dichloromethane at a temperature in the range −30° C. to 40° C. conveniently at or near 0° C. to give the phosphoryloxy compound.
Synthesis of Intermediates
A compound of the formula (X) may be known in the art or may be prepared from by (f) reacting a compound of the formula (XII):
wherein P2 is an hydroxy-protecting group, with a compound of the formula L2-R8, wherein L2 is a leaving group;
The reaction between a compound of the formula (XII) and a compound of the formula L2-R8 is conveniently performed under standard acylation or sulphonylation conditions. L1 is usually halogeno, for example chloro or bromo, hydroxy, mesyloxy or tosyloxy or an ‘activated’ hydroxy group. The precise conditions depending largely upon the nature of R8.
For example, when Y3 is —CO—, L2 may be hydroxy and the reaction is normally carried out in the presence of coupling agent such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide. Optionally, a base may be used, for example an organic base such as triethylamine. Suitable solvents are usually aprotic solvents, for example dimethylformamide, or chlorinated solvents, for example trichloromethane or dichloromethane. The temperature is usually in the range of about −30° C. to about 60° C., conveniently at or near ambient temperature.
When Y3 is —C(O)O—, L2 is usually an ‘activated’ hydroxy group. That is a group which acts as a leaving group in the same way as hydroxy, but is more labile. It can be formed in situ. An example, of an activated hydroxy group is 4-nitrophenoxy, in which case the compound R8-L2 can be formed by reacting a hydroxy group (R17—OH) with 4-nitrophenylchloroformate. The reaction is usually carried out in an organic solvent such as dichloromethane, acetonitrile or tetrahydrofuran, in a temperature range of about −20° C. to the reflux temperature of the solvent. In addition an organic base such as triethylamine or N-methylmorpholine is normally present. Alternatively, a compound of the formula (XII) can be reacted with 4-nitrophenylchloroformate and the resulting intermediate reacted with R17—OH under similar conditions to those described above for the reaction of a compound of the formula (XII) with a compound of the formula R8-L2 wherein L2 is 4-nitrophenoxy.
When Y3 is —CON(R18)—, L2 is preferably halogeno, particularly chloro. Alternatively when -A- is —CONH—, a compound of the formula (XII) can be reacted with an isocyanate of the formula C≡N—R17. These reactions are conveniently carried out in the presence of a base, particularly an organic base, such as triethylamine, pyridine or N-methylmorpholine, triethylamine, pyridine or N-methylmorpholine in a solvent such as an ether solvent for example tetrahydrofuran or in a chlorinated solvent for example dichloromethane at a temperature in the range from about —20° C. to the reflux temperature of the solvent. Alternatively, a compound of the formula (XII) can be reacted with 4-nitrophenylchloroformate and the resulting intermediate reacted with R17—NH2 under similar conditions to those described above for the reaction of a compound of the formula (XII) with a compound of the formula R8-L2 wherein L2 is 4-nitrophenoxy.
When —X1— is of the formula —SO2N(R8)—, L2 is preferably halogeno, for example chloro. The reaction is conveniently carried out in the presence of a base such as dimethylaniline, in a chlorinated solvent such as trichloromethane and at a temperature in the range from about −20° C. to about 60° C. More preferably in pyridine, at a temperature in the range from about −20° C. to about 60° C. A compound of the formula (XI) may be prepared by reacting a compound of the formula (X) with a compound of L1-X2-phenyl-COOH in which L1 is protected or a precursor of L1 is used, using similar conditions to those described for the formation of a compound of the formula (I) from a compound of the formula (X).
L1 can be deprotected or the precursor converted to L1 following the coupling with the compound of the formula (X).
A compound of the formula (XII) can be formed from a compound of the formula (X) or (XI) wherein R8 is hydrogen, using similar conditions to those described above for the formation of a compound of the formula (I).
Compounds of the formula R5—COOH may be known in the art or prepared by methods known in the art or analogous to those illustrated in the specific examples. The following description gives some general processes for preparing some compounds of the formula R5—COOH.
When R5 is of the formula -A-X1Y1—B, and X1 is —N(R10)CO— or —CON(R10)— then a compound of the formula R5—COOH can be formed by reacting a compound of the formula P1OOC-A-NHR19, wherein P1 is a carboxy-protecting group, with a compound of the formula HOOC—Y1—B, or of the formula P1OOC-A-COOH with a compound of the formula NH(R10)—Y1—B, under standard amide forming conditions. Similarly when X1 is of the formula —N(R10)SO2— or SO2N(R10)— a compound of the formula R5—COOH can be formed by reacting the appropriate amine and sulphonyl chloride under conditions known for the formation of a sulphonamide. Likewise a compound of the formula R5—COOH wherein X1 is —C(O)O— can be formed by reacting together the appropriate carboxylic acid and alcohol and when X1 is —N(R10)C(O)O—, by reacting together the appropriate amine and ROC(O)OR compound.
When R5 is of the formula R15—X2-phenyl, a compound of the formula R5—COOH can be formed by reacting together the appropriate L1-(CH2)r— or L1-CO-substituted benzoic acid, wherein the carboxylic group in the benzoic acid is protected during the course of the reaction, under similar conditions to that described for the reaction between a compound of the formula (XI) with R15.
When R5 is of the formula —(CH2)a-Y2—(CH2)b and —R15 a is 2 or 3 and b is 0, a compound of the formula R5—COOH can be formed by reacting R15 with succinic anhydride or glutaric anhydride, as appropriate. The reaction is normally carried out in an inert organic solvent such as dichloromethane, in a temperature range of 0° to 60° C., usually around ambient temperature.
When R5 is N,N-di-(C1-4alkyl)carbamoylC1-4alkyl and C1-4alkyl is ethyl or propyl, a compound of the formula R5—COOH can be formed by reacting the HN(C1-4alkyl)2 compound with succinic anhydride or glutaric anhydride as appropriate. The reaction is normally carried out in an inert organic solvent such as dichloromethane, in a temperature range of 0° to 60° C., usually around ambient temperature.
Acid addition salts of the compounds of formula I are prepared in a conventional manner by treating a solution or suspension of the free base I with about one equivalent of a pharmaceutically acceptable acid. Salts of compounds of formula I derived from inorganic or organic bases are prepared in a conventional manner by treating a solution or suspension of the free acid I with about one equivalent of a pharmaceutically acceptable organic or inorganic base. Alternatively both acid addition salts and salts derived from bases may be prepared by treatment of the parent compound with the appropriate ion-exchange resin in a standard fashion. Conventional concentration and recrystallistion techniques are employed in isolating the salts.
Compounds according to the invention are able to destroy vasculature that has been newly formed such as tumour vasculature while leaving unaffected normal, mature vasculature. The identification of compounds which selectively, and preferably potently, damage newly-formed vasculature is desirable and is the subject of the present invention. The ability of the compounds to act in this way may be assessed, for example, using one or more of the procedures set out below:
(a) Activity Against Tumour Vasculature Measured by Radioactive Tracer
This assay demonstrates the ability of compounds to damage selectively tumour vasculature.
Subcutaneous CaNT tumours were initiated by injecting 0.05 ml of a crude tumour cell suspension, approximately 106 cells, under the skin overlying the rear dorsum of 12-16 week-old mice. The animals were selected for treatment after approximately 3-4 weeks, when their tumours reached a geometric mean diameter of 5.5-6.5 mm. Compounds were dissolved in sterile saline and injected intraperitoneally in a volume of 0.1 ml per 10 g body weight. Tumour perfusion was measured 6 hours after intraperitoneal administration in tumour, kidney, liver, skin, muscle, gut and brain by the 86RbCl extraction technique (Sapirstein, Amer. Jnl. Physiol., 1958, 193, 161-168). Tissue radioactivity measured 1 minute after an intravenous injection of 86RbCl was used to calculate relative blood flow as a proportion of cardiac output (Hill and Denekamp, Brit. Jnl. Radiol., 1982, 55, 905-913). Five animals were used in control and treated groups. Results were expressed as a percentage of the blood flow in the corresponding tissues in vehicle treated animals.
(b) Activity Against Tumour Vasculature Measured by Fluorescent Dye
This assay demonstrates the ability of compounds to damage tumour vasculature.
Tumour functional vascular volume in CaNT tumour-bearing mice was measured using the fluorescent dye Hoechst 33342 according to the method of Smith et al (Brit. Jnl. Cancer 1988, 57, 247-253). Five animals were used in control and treated groups. The fluorescent dye was dissolved in saline at 6.25 mg/ml and injected intravenously at 10 mg/kg 24 hours after intraperitoneal drug treatment. One minute later, animals were killed and tumours excised and frozen; 10 μm sections were cut at 3 different levels and observed under UV illumination using an Olympus microscope equipped with epifluorescence. Blood vessels were identified by their fluorescent outlines and vascular volume was quantified using a point scoring system based on that described by Chalkley, (Jnl. Natl. Cancer Inst., 1943, 4, 47-53). All estimates were based on counting a minimum of 100 fields from sections cut at the 3 different levels.
The ability of the compounds to bind to preparations of mammalian tubulin can be evaluated by a number of methods available in the literature, for example by following temperature initiated tubulin polymerisation by turbidity in the absence and presence of the compound (for example O. Boye et al Med. Chem. Res., 1991, 1, 142-150).
The activity of N-[3-amino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide, (V. Fernholz Justus Liebigs Ann., 1950, 568, 63-72), against tumour vasculature was measured by the fluorescent dye method described above. This compound decreased perfused vascular volume by 88% relative to control when dosed at 50 mg/kg intraperitoneally. The IC50 of this compound in a tubulin polymerisation assay was 58 micromolar (O. Boye et al Med. Chem. Res., 1991, 1, 142-150).
(c) HUVEC Detachment Assay
This assay examined the effects of compounds on the adherence of HUVECs to tissue culture plasticware.
HUVECs were plated in 0.2% gelatin-coated 12 well tissue culture plates at a concentration of 3×104 cells per well in 1 ml TCS medium. After 24 hours, when the cells were at ˜30% confluency, the cells were dosed with compound for 40 minutes at 37° C., 5% CO2. After this incubation the medium containing drug was pipetted off, and the cells were then gently washed in 2 mls of HBSS (Hanks' Balanced Salt Solution purchased from Life Technologies Ltd, Paisley UK; Catalogue # 24020-083) to remove any detached cells. The washing solution was then removed, and the adherent cells remaining were trypsinised using 300 μl of 1× Trypsin-EDTA solution (Life Technologies Ltd, Paisley, UK; Catalogue # 43500-019) at ambient temperature for 2 minutes. The trypsinised cells were then made up to 1 ml with TCS Biologicals medium, then centrifuged at 2000 rpm for 2 minutes. The cell pellet was then resuspended in a volume of 50 μl of TCS Biologicals medium. Total cell counts were obtained by counting the cells on a haemocytometer. The amount of cell detachment was calculated by comparing the number of cells remaining attached following treatment with the number in undosed control wells.
(d) Hras5 Necrosis Model
NIH 3T3 fibroblasts transfected with Harvey ras, clone 5, (Hras5 cells) were kept in continual passage in Dulbecco's modifed Eagles medium (DMEM) containing 10% foetal bovine serum (FBS) and 1% glutamine, at 37° C. in a humidified incubator gassed with 7.5% carbon dioxide and 92.5% oxygen. Cells were implanted subcutaneously into the left flank of male nude mice (8-10 weeks of age) at an inoculum of 2×105 cells/mouse. Tumours were measured using calipers and randomised into groups of 2-4 mice between days 9-14 after implant. Mice were dosed with compounds, either intravenously or intraperitoneally, once on day of randomisation and culled 24 hours after dosing. Compounds were dissolved in 20% hydroxypropyl beta cyclodextrin in physiological saline at pH 7 and dosed in a volume of 0.1 ml per 10 g body weight. Tumours were excised, weighed and placed in buffered formalin. Area of necrosis in individual tumours was assessed from a haematoxylin/eosin stained-slide by a pathologist and scored from 0, meaning no significant change, to 10, meaning 91-100% necrosis. The activity of examples 5 and 7 (described hereinafter) against tumour vasculature was measured by the fluorescent dye method described hereinabove. Example 1 scored 6.6 at 25 mg/kg.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula I as defined hereinbefore or a pharmaceutically acceptable salt, solvate or pro-drug thereof, in association with a pharmaceutically acceptable excipient or carrier.
The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for nasal administration or administration by inhalation, for example as a powder or solution, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical administration for example as an ointment or cream or for rectal administration for example as a suppository. In general the above compositions may be prepared in a conventional manner using conventional excipients.
The compositions of the present invention are advantageously presented in unit dosage form. The compound will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square metre body area of the animal, i.e. approximately 0.1-100 mg/kg. A unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.
As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
According to a further aspect of the present invention there is provided a compound of the formula I or a pharmaceutically acceptable salt, solvate or pro-drug thereof as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.
A further feature of the present invention is a compound of formula I, or a pharmaceutically acceptable salt, solvate or pro-drug thereof, for use as a medicament, conveniently a compound of formula I, or a pharmaceutically acceptable salt, solvate or pro-drug thereof, for use as a medicament for producing a vascular damaging effect in a warm-blooded animal such as a human being.
Thus according to a further aspect of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal such as a human being.
According to a further feature of the invention there is provided a method for producing a vascular damaging effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate or pro-drug thereof as defined hereinbefore.
According to a further aspect of the present invention there is provided a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition, when dosed in divided doses (also known as split doses) produces a greater anti-tumour effect than when a single dose is given.
Anti-tumour effects of a method of treatment of the present invention include but are not limited to, inhibition of tumour growth, tumour growth delay, regression of tumour, shrinkage of tumour, increased time to re-growth of tumour on cessation of treatment, slowing of disease progression. It is expected that when a method of treatment of the present invention is administered to a warm-blooded animal such as a human, in need of treatment for cancer involving a solid tumour, said method of treatment will produce an effect, as measured by, for example, one or more of: the extent of the anti-tumour effect, the response rate, the time to disease progression and the survival rate.
According to a further aspect of the present invention there is provided a method for the production of a vascular damaging effect in a warm-blooded animal such as a human, which comprises administering to said animal in divided doses an effective amount of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition.
According to a further aspect of the present invention there is provided a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal in divided doses an effective amount of a compound of formula (I) or pharmaceutically-acceptable salt or solvate thereof, preferably in the form of a pharmaceutical composition.
According to a further aspect of the present invention there is provided a medicament comprising two or more fractions of doses of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition, which together add up to a total daily dose, for administration in divided doses for use in a method of treatment of a human or animal body by therapy.
According to a further aspect of the present invention there is provided a kit comprising two or more fractions of doses of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition, which together add up to a total daily dose, for administration in divided doses.
According to a further aspect of the present invention there is provided a kit comprising:
According to a further aspect of the present invention there is provided a kit comprising:
According to a further aspect of the present invention there is provided the use of compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for administration in divided doses for use in the production of a vascular damaging effect in a warm-blooded animal such as a human.
According to a further aspect of the present invention there is provided the use of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for administration in divided doses for use in the production of an anti-cancer effect in a warm-blooded animal such as a human.
According to a further aspect of the present invention there is provided the use of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for administration in divided doses for use in the production of an anti-tumour effect in a warm-blooded animal such as a human.
Divided doses, also called split doses, means that the total dose to be administered to a warm-blooded animal, such as a human, in any one day period (for example one 24 hour period from midnight to midnight) is divided up into two or more fractions of the total dose and these fractions are administered with a time period between each fraction of about greater than 0 hours to about 10 hours, preferably about 1 hour to about 6 hours, more preferably about 2 hours to about 4 hours. The fractions of total dose may be about equal or unequal.
Preferably the total dose is divided into two parts which may be about equal or unequal.
The time intervals between doses may be for example selected from:
about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours and about 6 hours.
The time intervals between doses may be any number (including non-integers) of minutes between greater than 0 minutes and 600 minutes, preferably between 45 and 375 minutes inclusive. If more than two doses are administered the time intervals between each dose may be about equal or unequal.
Preferably two doses are given with a time interval in between them of greater than or equal to 1 hour and less than 6 hours.
More preferably two doses are given with a time interval in between them of greater than or equal to two hours and less than 5 hours.
Yet more preferably two doses are given with a time interval in between them of greater than or equal to two hours and less than or equal to 4 hours.
Particularly the total dose is divided into two parts which may be about equal or unequal with a time interval between doses of greater than or equal to about two hours and less than or equal to about 4 hours.
More particularly the total dose is divided into two parts which may be about equal with a time interval between doses of greater than or equal to about two hours and less than or equal to about 4 hours.
For the avoidance of doubt the term ‘about’ in the description of time periods means the time given plus or minus 15 minutes, thus for example about 1 hour means 45 to 75 minutes, about 1.5 hours means 75 to 105 minutes. Elsewhere the term ‘about’ has its usual dictionary meaning.
The antiangiogenic treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment in addition to the antiangiogenic treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy. Such chemotherapy may include the following categories of therapeutic agent: (i) other antiangiogenic agents that work by different mechanisms from those defined hereinbefore (for example linomide, inhibitors of integrin αvβ3 function, angiostatin, endostatin, razoxin, thalidomide) and including vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (RTKIs) (for example those described in International Patent Applications Publication Nos. WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354 the entire disclosure of which documents is incorporated herein by reference); (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrazole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5α-dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example epidermal growth factor (EGF), platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors); (iii) biological response modifiers (for example interferon); (iv) antibodies (for example edrecolomab); and (v) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, n-dthramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophospharide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincristine and taxoids like taxol, taxotere); enzymes (for example asparaginase); thymidylate synthase inhibitors (for example raltitrexed); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan, irinotecan).
As stated above the compounds defined in the present invention are of interest for their vascular damaging effects. Such compounds of the invention are expected to be useful in the prophylaxis and treatment of a wide range of disease states where inappropriate angiogenesis occurs including cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation. In particular such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin.
In addition to their use in therapeutic medicine, the compounds of formula I and their pharmaceutically acceptable salts, solvates and pro-drugs are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of vascular damaging agents in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
It is to be understood that where the term “ether” is used anywhere in this specification it refers to diethyl ether.
The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated:
(i) evaporations were carried out by rotary evaporation invacuo and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;
(ii) operations were carried out at ambient temperature, that is in the range 18-25° C. and under an atmosphere of an inert gas such as argon or nitrogen;
(iii) yields are given for illustration only and are not necessarily the maximum attainable;
(iv) the structures of the end-products of the formula I were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet, quin, quintet;
(v) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), infra-red (IR) or NMR analysis;
Abbreviations
A solution of 5-(4-acetylpiperazin-1-yl)-5-oxopentanoic acid (0.308 g; 1.27 mmol), EDCI (0.244 g; 1.27 mmol), DMAP (0.036 g; 0.29 mmol) in dichloromethane (30 ml) was stirred under argon atmosphere for 30 minutes. N-acetyl colchinol [International Patent Application No. PCT/GB98/01977] (0.350 g; 0.98 mmol) was then added and the mixture was stirred overnight. After evaporation to dryness, the residue was purified by flash chromatography, eluting with dichloromethane/methanol (95/5) to give the title compound after evaporation of the appropriate fractions and trituration in ether/pentane.
Yield: 82%
1H NMR (DMSO-d6): 1.45-1.50 (m, 1H); 1.51-1.75 (m, 1H); 1.87 (s, 3H); 1.79-1.94 (m, 1H); 1.94-2.11 (m, 2H); 2.02 (s, 3H); 2.10-2.24 (m, 1H); 2.52-2.62 (m, 1H, signal partially obscured by DMSO peak); 2.74-2.85 (m, 1H); 2.88-2.98 (m, 1H); 3.14-3.24 (m, 1H); 3.28-3.33 (m, 1H); 3.51 (s, 3H); 3.78 (s, 3H); 3.78-3.89 (m, 1H); 3.85 (s, 3H); 4.24-4.33 (m, 1H); 4.49-4.59 (m, 1H); 6.80 (s, 1H); 7.07 (s, 1H); 7.09 (dd, 1H); 7.35 (d, 1H); 3.39 (d, 1H).
MS-ESI: 582 [MH]+
The starting material as follows:
A solution of glutaric anhydride (1.6 g; 14 mmol) and N-acetylpiperazine (1.5 g; 12 mmol) in dichloromethane (20 ml) was stirred overnight. The resulting precipitate was filtered, washed with ether and dried to give 5-(4-acetylpiperazin-1-yl)-5-oxopentanoic acid as a white solid.
Yield: 83%
1H NMR (CDCl3): 1.98 (m, 2H); 2.13 (s, 3H); 2.46 (m, 4H); 3.47 (m, 4H); 3.64 (m, 4H).
The compound was prepared using a similar method to that described in Example 1, but using 4-(4-acetylpiperazin-1-yl)-4-oxobutanoic acid in place of 5-(4-acetylpiperazin-1-yl)-5-oxopentanoic acid.
Yield: 67%
1H NMR (DMSO-d6): 1.81-1.93 (m, 1H); 1.86 (s, 3H); 1.98-2.10 (m, 1H); 2.02 (d, 3H); 2.11-2.23 (m, 1H); 2.52-2.59 (m, 1H, signal partially obscured by DMSO peak); 2.71-2.85 (m, 4H); 3.27-3.54 (m, 8H); 3.51 (s, 3H); 3.78 (s, 3H); 3.84 (s, 3H); 4.47-4.58 (m, 1H); 6.80 (s, 1H); 7.04 (dd, 1H); 7.06 (d, 1H); 7.34 (d, 1H); 8.41 (d, 1H).
MS-ESI: 568 [MH]+
The starting material was prepared as follows:
A solution of succinic anhydride (1.72 g; 17 mmol) and N-acetyl piperazine (2 g; 15.6 mmol) in dichloromethane (40 ml) was stirred overnight. After evaporation to dryness, the residue was triturated in ether/pentane to give 4-(4-acetylpiperazin-1-yl)-4-oxobutanoic acid as a solid.
Yield: 95%
1H NMR (CDCl3): 2.13 (s, 3H); 2.70 (m, 4H); 3.48 (m, 4H); 3.66 (m, 4H).
A solution of (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3-chloromethylbenzoate (0.408 g; 0.8 mmol), N-acetylpiperazine (0.144 g; 1.12 mmol) and sodium iodide (0.06 g; 0.4 mmol) in acetonitrile (6 ml) was stirred under argon atmosphere at room temperature overnight. After evaporation to dryness, the mixture was purified by flash chromatography eluting with dichloromethane/ethanol (92/8) to give the title compound as a white solid.
Yield: 69%
1H NMR (DMSO-d6): 1.81-1.97 (m, 1H); 1.87 (s, 3H); 1.99 (s, 3H); 2.04-2.28 (m, 2H); 2.28-2.38 (m, 2H); 2.39-2.48 (m, 2H); 2.48-2.55 (m, 1H, signal partially obscured by DMSO peak); 3.42-3.51 (m, 4H); 3.56 (s, 3H); 3.64 (s, 2H); 3.81 (s, 3H); 3.87 (s, 3H); 4.54-4.67 (m, 1H); 6.84 (s, 1H); 7.25 (s, 1H); 7.26 (dd, 1H); 7.43 (d, 1H); 7.52 (dd, 1H); 7.72 (d, 1H); 8.10 (d, 1H); 8.12 (s, 1H); 8.40 (d, 1H).
MS-ESI: 602 [MH]+
The title compound was prepared using a similar method to that in Example 1 but replacing 5-(4-acetylpiperazin-1-yl)-5-oxopentanoic acid by 4-{3-(4-methylpiperazin-1-yl)propionylamino]benzoic acid.
Yield: 55%
1H NMR (DMSO-d6): 1.78-2.75 (m, 14H); 1.88 (s, 3H); 2.17 (s, 3H); 2.64 (t, 2H); 3.56 (s, 3H); 3.81 (s, 3H); 3.83 (s, 3H); 4.51-4.65 (m, 1H); 6.82 (s, 1H); 7.19-7.24 (m, 2H); 7.40 (d, 1H); 7.82 (d, 2H); 8.12 (d, 2H); 8.39 (d, 1H); 10.53 (s, 1H).
MS-ESI: 631 [MH]+
The starting material was prepared as follows:
A solution of methyl 4-aminobenzoate (0.76 g; 5 mmol), EDCI (1.25 g; 6.5 mmol), DMAP (0.13 g; 1 mmol), 3-(4-methylpiperazin-1-yl)propanoic acid (1.49 g; 7.5 mmol) and triethylamine (1.05 ml; 7.5 mmol) in dichloromethane (20 ml) was stirred under argon atmosphere for 2 days. The mixture was extracted with ethyl acetate, evaporated and purified by flash chromatography eluting with dichloromethane/methanol to give methyl 4-[3-(4-methylpiperazin-1-yl)propionylamino]benzoate.
Yield: 46%
1H NMR (DMSO-d6): 2.14 (s, 3H); 2.07-2.70 (m, 10H); 2.62 (t, 2H); 3.82 (s, 3H); 7.71 (d, 2H); 7.91 (d, 2H); 10.41 (s, 1H).
MS-ESI: 306 [MH]+
A solution of methyl 4-[3-(4-methylpiperazin-1-yl) propionylamino]benzoate (0.69 g; 2.26 mmol) in methanol (10 ml) was treated with 2N sodium hydroxide solution (1.25 ml; 2.48 mmol) at 60° C. for 6 hours. After evaporation to dryness, the residue was triturated in acetone. The insoluble material was taken-up in water and the pH adjusted to 6.5 with 2N HCl. After evaporation, the residue was triturated in acetone to give 4-[3-(4-methylpiperazin-1-yl)propionylamino]benzoic acid as a solid.
Yield: 98%.
1H NMR (DMSO-d6): 2.17 (s, 3H); 2.10-2.70 (m, 10H); 2.64 (t, 2H); 7.69 (d, 2H); 7.88 (d, 2H).
A solution (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3-(piperazin-1-ylmethyl)benzoate (0.2 g; 0.357 mmol) and trimethylsilyl isocyanate (0.290 ml; 2.14 mmol) in dichloromethane (3 ml) was stirred at ambient temperature overnight. After evaporation to dryness, the residue was purified by flash chromatography, eluting with dichloromethane/ethanol (85/15) to give the title compound.
Yield: 87%
1H NMR (DMSO-d6: 1.80-1.96 (m, 1H); 1.88 (s, 3H); 2.00-2.28 (m, 2H); 2.35 (m, 4H); 2.52-2.59 (m, 1H, signal partially obscured by DMSO peak); 3.30 (m, 4H); 3.56 (s, 3H); 3.63 (s, 2H); 3.81 (s, 3H); 3.87 (s, 3H); 4.55-4.54 (m, 1H); 5.94 (s, 2H); 6.82 (s, 1H); 7.23 (s, 1H); 7.25 (dd, 1H); 7.41 (d, 1H); 7.59 (t, 1H); 7.70 (d, 1H); 8.07 (d, 1H); 8.10 (s, 1H); 8.39 (d, 1H).
MS-ESI: 603 [MH]+
The starting material was prepared as follows
A solution of (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3-chloromethylbenzoate (0.714 g; 1.4 mmol), N-tert-butoxycarbonyl piperazine (0.417 g; 2.24 mmol) and sodium iodide (0.21 g; 1.4 mmol) in dichloromethane (20 ml) was stirred at 45° C., under argon atmosphere for 24 hours. After evaporation to dryness, the residue was purified by flash chromatography eluting with dichloromethane/ethanol (95/5) to give (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3-(4-tert-butoxycarbonylpiperazin-1-ylmethyl)benzoate.
Yield: 55%
1H NMR (DMSO-d6): 1.39 (s, 9H); 1.81-1.96 (m, 1H); 1.86 (s, 3H); 2.02-2.26 (m, 2H); 2.36 (t, 4H); 2.53-2.60 (m, 1H, signal partially obscured by DMSO peak); 3.34 (m, 8H); 3.54 (s, 3H); 3.61 (s, 2H); 3.80 (s, 3H); 3.85 (s, 3H); 4.53-4.64 (m, 1H); 6.82 (s, 1H); 7.23 (s, 1H); 7.24 (dd, 1H); 7.41 (d, 1H); 7.59 (t, 1H); 7.70 (d, 1H); 8.07 (d, 1H); 8.10 (s, 1H); 8.38 (d, 1H).
MS-ESI: 660 [MH]+
A solution of (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3-(4-tert-butoxycarbonylpiperazin-1-ylmethyl)benzoate (0.711 g; 1.07 mmol) in dichloromethane (15 ml) was treated with 2.5N HCl/ether (3.5 ml) at ambient temperature for 1 hour. After evaporation, the residue was taken-up in water, the pH was adjusted to 5 with 2N sodium hydroxide solution and the solution purified on reverse phase silica, eluting with a gradient of 40-50% methanol/ammonium carbonate buffer (2 g/l pH 7) to give (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3-(piperazin-1-ylmethyl)benzoate.
Yield: 55%
1H NMR (DMSO-d6): 1.82 -1.97 (m, 1H); 1.88 (s, 3H); 2.02-2.26 (m, 2H); 2.33 (bs, 4H); 2.51-2.60 (m, 1H); 2.71 (m, 4H); 3.56 (s, 3H); 3.82 (s, 3H); 3.87 (s, 3H); 4.45-4.64 (m, 1H); 6.84 (s, 1H); 7.24 (s, 1H); 7.25 (dd, 1H); 7.41 (d, 1H); 7.58 (t, 1H); 7.69 (d, 1H); 8.05 (d, 1H); 8.08 (s, 1H); 8.38 (d, 1H).
MS-ESI: 560 [MH]+
(5S)-5-Acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl N-acetylpiperidin-1-ylcarboxylate
The title compound was prepared using a similar method to that described in Example 1, but 4-acetylpiperidin-1-ylcarboxylic acid was used in place of 5-(4-acetylpiperazin-1-yl)-5-oxopentanoic acid:
Yield: 79%
1H NMR (DMSO-d6): 1.45-1.60 (m, 1H); 1.61-1.75 (m, 1H); 1.88-1.93 (m, 2H); 1.87 (s, 3H); 1.94-2.09 (m, 2H); 2.02 (s, 3H); 2.10-2.24 (m, 1H); 2.53-2.60 (m, 1H, signal partially obscured by DMSO peak); 2.75-2.85 (m, 1H); 2.88-2.98 (m, 1H); 3.14-3.25 (m, 1H); 3.26 (bs, 1H); 3.50 (s, 3H); 3.78 (s, 3H); 3.81 (bs, 1H); 3.84 (s, 3H); 4.23-4.33 (m, 1H); 4.49-4.59 (m, 1H); 6.80 (s, 1H); 7.06 (s, 1H); 7.08 (dd, 1H); 7.35 (d, 1H); 8.39 (d, 1H).
MS-ESI: 511 [MH]+
A 2.4 N solution of sulphuric acid in methanol (4 ml) was added at 3° C. under argon atmosphere, to a solution of (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3-{N—N-di-[2-(tert-butyldimethylsilyloxy)ethyl]carbamoyl}propanoate (0.7 g; 0.906 mmol) in methanol (15 ml). After stirring at 3° C. for 45 mins, a mixture of ethyl acetate (100 ml) and saturated aqueous sodium hydrogen carbonate solution (75 ml) was added. The organic phase was washed with water, dried and was purified by flash chromatography eluting dichloromethane/methanol (92/8) to give the title compound.
Yield: 66%
1H NMR (DMSO-d6): 1.81-1.96 (m, 1H); 1.89 (s, 3H); 1.98-2.56 (m, 2H); 2.55-2.65 (m, 1H, signal partially obscured by DMSO peak); 2.80 (bs, 4H); 4.37-4.63 (m, 8H); 3.53 (s, 3H); 3.80 (s, 3H); 3.86 (s, 3H); 4.49-4.60 (m, 1H); 4.69 (t, 1H); 4.88 (t, 1H); 6.80 (s, 1H); 7.02-7.07 (m, 2H); 7.34 (d, 1H). 8.40 (d, 1H).
MS-ESI: 545 [MH]+
The starting material was prepared as follows:
Succinic anhydride (2.64 g; 0.026 mol) was added under argon atmosphere to a solution of N—N-di-[2-(tert-butyldimethylsilyloxy)ethyl]amino [Synthesis (19997), 6, 643-648] (8 g; 0.024 mol) in dichloromethane. The mixture was stirred at ambient temperature overnight. After filtration of the insoluble, the filtrate was evaporated and dried to give 3-{N,N-di[2-(tert-butyldimethylsilyloxy)ethyl]carbamoyl}propanoic acid.
Yield: 96%
1H NMR (CDCl3): 0.04 (s, 6H); 0.05 (s, 6H); 0.87 (s, 9H); 0.88 (s, 9H); 2.62-2.69 (m, 2H); 2.83-2.90 (m, 2H); 3.52 (t, 2H); 3.58 (t, 2H); 3.75 (t, 2H); 3.78 (t, 2H).
A solution of 3-{N,N-di[2-(tert-butyldimethylsilyloxy)ethyl]carbamoyl}propanoic acid (0.552 g; 1.27 mmol), EDCI (0.244 g; 1.27 mmol), DMAP (0.036 g; 0.294 mmol) in dichloromethane (30 ml) was stirred under argon atmosphere for 30 mins. N-acetyl colchinol (0.35 g; 0.98 mmol) was added and the mixture was stirred at ambient temperature overnight. After evaporation to dryness, the residue was purified by flash chromatography, eluting with ethyl acetate/petroleum ether (70/30) to give 5(S)-5-acetylamino-9,10,1 1-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3 {N—N-di[2-(tert-butyl-dimethylsilyloxy]ethyl}carbamoyl propanoate.
Yield : 74%
1H NMR (DMSO-d6): 0.03 (s, 6H); 0.04 (s, 6H); 0.86 (s, 9H); 0.87 (s, 9H); 1.83-1.94 (m, 1H); 1.80 (s, 3H); 2.00-2.11 (m, 1H); 2.12-2.24 (m, 1H); 2.53-2.60 (m 1H, signal partially obscured by DMSO peak); 2.72-2.78 (m, 2H); 2.78-2.86 (m, 2H); 3.42 (t, 2H); 3.52 (s, 3H); 3.53 (t, 2H); 3.57 (t, 2H); 3.75 (t, 2H); 3.80 (s, 3H); 3.85 (s, 3H); 4.50-4.60 (m, 1H); 6.81 (s, 1H); 7.03 (dd, 1H); 7.07 (d, 1H); 7.34 (d, 1H); 8.41 (d, 1H).
The title compound was prepared using a similar method to that described in Example 7, but using (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c}cyclohepten-3-yl 4-N,N-di[2-(tert-butyldimethylsilyloxy)ethyl]carbamoyl}butanoate in place of (5S)-5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl 3 {N,N-di[2-(tert-butyl-dimethylsilyloxy)ethyl]carbamoyl}propanoate.
Yield: 37%
1H NMR (DMSO-d6): 1.83-1.92 (m, 2H); 1.87 (s, 3H); 1.98-2.10 (m, 1H); 2.11-2.22 (m, 1H); 2.48 (t, 2H, signal partially obscured by DMSO peak); 2.52-2.56 (m, 1H, signal partially obscured by DMSO peak); 2.63 (t, 2H); 3.35 (t, 2H); 3.41 (t, 2H); 3.44-3.50 (m, 2H); 3.50-3.57 (m, 2H); 3.51 (s, 3H); 3.78 (s, 3H); 3.84 (s, 3H); 4.50-4.60 (m, 1H); 4.67 (t, 1H); 4.85 (t, 1H); 6.80 (s, 1H); 7.07 (s, 1H); 7.09 (dd, 1H); 7.34 (d, 1H). 8.38 (d, 1H).
MS-ESI: 581 [MNa]+
The starting material was prepared as follows:
A solution of glutaric anhydride (0.753 g; 6.6 mmol) and N,N-di{2-(tert-butyldimethylsilyloxy)ethyl]amino (2 g; 6.6 mmol) in dichloromethane (40 ml) was stirred overnight. After evaporation to dryness the residue was triturated in pentane to give a solid which was filtered. The filtrate was evaporated to give 4-{N,N-di[2-(tert-butyldimethylsilyloxy)ethyl]carbamoyl}butanoic acid as an oil.
Yield: 95%
1H NMR (DMSO-d6): 0.03 (s, 6H); 0.04 (s, 6H); 0.86 (s, 9H); 0.87 (s, 9H); 1.70 (m, 2H); 2.23 (t, 2H); 2.38 (t, 2H); 3.38 (t, 2H); 3.46 (t, 2H); 3.65 (t, 2H); 3.70 (t, 2H).
4-{N,N-di[2-(tert-Butyldimethylsilyloxy)ethyl]carbamoyl}butanoic acid was reacted with N-acetyl colchinol using the similar conditions to that in Example 7, but using 4-{N,N-di[2-(tert-butyldimethylsilyloxy)ethyl]carbamoyl}butanoic acid in place of 3-{(N,N-di[2-(tert-butyldimethylsilyloxy)ethyl]carbamoyl}propanoic acid.
Yield: 92%
1H NMR (DMSO-d6): 0.04 (s, 12H); 0.86 (s, 9H); 0.87 (s, 9H); 1.83-1.94 (m, 2H); 1.88 (s, 3H); 2.00-2.11 (m, 1H); 2.12-2.24 (m, 1H); 2.48 (t, 2H, signal partially obscured by DMSO peak); 2.51-2.54 (m, 1H, signal partially obscured by DMSO peak); 2.65 (t, 2H); 3.41 (t, 2H); 3.50 (t, 2H); 3.53 (s, 3H); 3.64-3.76 (m, 2H); 3.80 (s, 3H); 3.86 (s, 3H); 4.51-4.61 (m, 1H); 6.81 (s, 1H); 7.08 (dd, 1H); 7.09 (d, 1H); 7.36 (d, 1H); 7.99 (s, 1H); 8.40 (d, 1H).
| Number | Date | Country | Kind |
|---|---|---|---|
| 00401978.2 | Jul 2000 | EP | regional |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/GB01/02966 | 7/4/2001 | WO | 1/6/2003 |
